New Delhi: Zee News reporter Pooja Makkar became the first female journalist to receive the coronavirus vaccine, Covaxin, in India on Monday (January 4). Covaxin is the indigenous vaccine developed by Bharat Biotech against COVID-19 in collaboration with ICMR.
Pooja Makkar got vaccinated at AIIMS, Delhi today afternoon at 2pm after the necessary tests. He remained under observation and shared his experience later. The Zee News reporter, who is a health reporter, has reported extensively on the COVID-19 pandemic and its aftermath, as well as being aware of the vaccines being developed in the country to combat this deadly virus.
Speaking of her experience, Pooja said that after 5.30 am she has not felt any complications, adding that she decided to undergo the vaccination as “it was necessary to instill confidence among common people that the vaccine is completely safe.”
When asked about any physical or internal impacts after vaccination, he boldly said in front of the camera that he is not having any problems so far.
Pooja has been given a sheet to fulfill the points asked about her experience. You have also been provided with a helpline number to contact AIIMS in case you run into any problems in the next few days.
After 28 days, you will receive another injection of Covaxin, as it is needed twice to stay safe from the deadly pandemic. Pooja stayed on the front line as she covered all aspects of the deadly virus.
In particular, the Comptroller General of Medicines of India (DCGI) has recently granted approval for the emergency use of the two coronavirus vaccines.
Covaxin, the indigenous vaccine developed by Bharat Biotech against COVID-19 in collaboration with ICMR, is 200 percent safe, the company’s president and CEO Dr. Krishna Ella told ANI. In addition, he said that so far it has shown less than 10 percent adverse reactions in trials.
Dr. Ella’s comments came a day after DGCI granted permission for the restricted emergency use of Covaxin. The indigenous vaccine has been developed by Bharat Biotech in collaboration with the Indian Council for Medical Research (ICMR) – National Institute of Virology (NIV).
In a previous statement, Bharat Biotech had previously said that Covaxin is a highly purified, inactivated, two-dose SARS-CoV2 vaccine manufactured on a vero cell manufacturing platform with an excellent safety record of more than 300 million doses. .
Earlier on Sunday, COVID-19 vaccines from the Serum Institute of India and Bharat Biotech received permission for restricted use in an emergency situation by the Controller General of Drugs of India (DCGI).
.
